In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Association of cyp11b2 gene polymorphism of aldosterone-synthase with the relative risk of st segment elevation myocardial infarction

Session Poster Session 3 - ST Elevation Acute Coronary Sydrome

Speaker Associate Professor Irina Vishnevskaya

Event : Acute Cardiovascular Care 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : ST-Elevation Myocardial Infarction (STEMI)
  • Session type : Poster Session

Authors : IR Vyshnevska (Kharkiv,UA), OV Petyunina (Kharkiv,UA), MP Kopytsya (Kharkiv,UA)

IR Vyshnevska1 , OV Petyunina1 , MP Kopytsya1 , 1Government institution“L.T. Malaya Therapy National institute of the National academy of medical sci - Kharkiv - Ukraine ,

European Heart Journal Supplement ( 2018 ) 7 ( Supplement ), S196

Background: The pathway of tissue aldosterone production may exist in the heart and may be an important contributory factor to myocardial fibrosis and cardiac remodeling in the failing heart. CYP11B2 (aldosterone synthase) catalases is the final step of aldosterone production.
Purpose: to determine the link between CYP11B2 - 344?? gene polymorphism and risk factors, course of ST segment elevation myocardial infarction (STEMI) with considering of genetic inheritance models.
Methods: 85 patients with STEMI were examined, from them, 68 (80%) male and 17 (20%) female, mean age was (58,94±10,16) years. Allele polymorphism -?344? of CYP11B2 gene by polymerase chain reaction in real time was determined. All analyses were performed with statistics software package Statistica 8.0 (Stat SoftInc, USA), Microsoft Office Ex?el 2003. For a deeper understanding of association of CYP11B2-gene polymorphism, codominant allele, dominant and recessive models of inheritance were used. Research was planned as a case-only design.
Results: Due to odds ratio the relative risk of STEMI occurrence in investigated patients with TT-genotype rises with the presence of arterial hypertension (AH) OR=8,89; 95% CI [1,41-36,57], ?TT-CC=0,02 (codominant allele model of inheritance). In the group of patients with TT-genotype compared to ??+?? anxiety-depressive conditions were more common (?=0,02), AH tendency also occurs more often (p=0,06) (dominant inheritance model). Due to odds ratio, relative risk of STEMI occurrence in the examined patients with ??+??-genotype becomes higher in the presence of AH, OR=3,27; 95% CI [1,05-9,86], ?=0,037 (recessive inheritance model).
Conclusions: ??+??-genotype compared to ?? represents 3,27-fold has a higher relative risk of STEMI in the patients with arterial hypertension (?=0,037). Arterial hypertension leads to 8,89-fold increase of relative risk of STEMI in patients with ??-genotype compared to ?? (?=0,02). Anxiety-depressive conditions in patients with STEMI occur more often in ??-genotype compared to ??, ??+?? polymorphism, ??+?? compared -344??.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are